Literature DB >> 31285781

NONPARAMETRIC INFERENCE FOR IMMUNE RESPONSE THRESHOLDS OF RISK IN VACCINE STUDIES.

Kevin M Donovan1, Michael G Hudgens1, Peter B Gilbert2.   

Abstract

An important objective in vaccine studies entails identifying an immune response which is predictive of disease risk. Nonparametric methods are developed for inference on immune response thresholds that are associated with specified levels of disease risk, including where the risk level is zero. This threshold is defined as the minimum immune response value above which disease risk is less than or equal to the desired level. The proposed nonparametric methods are compared to previously developed parametric methods in simulation studies. The methods are extended for use in studies that only measure the immune response in a subset of participants, such as case-cohort or case-control studies, and with right censored time to disease outcomes. Finally, these methods are used to estimate neutralizing antibody thresholds for virologically confirmed dengue risk using data from two recent dengue vaccine trials.

Entities:  

Keywords:  case-cohort sampling; nonparametric; risk threshold; vaccine studies

Year:  2019        PMID: 31285781      PMCID: PMC6613658          DOI: 10.1214/18-AOAS1237

Source DB:  PubMed          Journal:  Ann Appl Stat        ISSN: 1932-6157            Impact factor:   2.083


  23 in total

1.  Use of statistical models for evaluating antibody response as a correlate of protection against varicella.

Authors:  Ivan S F Chan; Shu Li; Holly Matthews; Christina Chan; Rupert Vessey; Jerald Sadoff; Joseph Heyse
Journal:  Stat Med       Date:  2002-11-30       Impact factor: 2.373

Review 2.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Authors:  Luis Jódar; Jay Butler; George Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith Klugman; Brian Plikaytis; George Siber; Robert Kohberger; Ih Chang; Thomas Cherian
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

3.  Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response.

Authors:  C J White; B J Kuter; A Ngai; C S Hildebrand; K L Isganitis; C M Patterson; A Capra; W J Miller; D L Krah; P J Provost
Journal:  Pediatr Infect Dis J       Date:  1992-01       Impact factor: 2.129

4.  A model for immunological correlates of protection.

Authors:  Andrew J Dunning
Journal:  Stat Med       Date:  2006-05-15       Impact factor: 2.373

5.  Multiple-imputation for measurement-error correction.

Authors:  Stephen R Cole; Haitao Chu; Sander Greenland
Journal:  Int J Epidemiol       Date:  2006-05-18       Impact factor: 7.196

6.  A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix.

Authors:  J CORNFIELD
Journal:  J Natl Cancer Inst       Date:  1951-06       Impact factor: 13.506

Review 7.  Meningococcal surrogates of protection--serum bactericidal antibody activity.

Authors:  Ray Borrow; Paul Balmer; Elizabeth Miller
Journal:  Vaccine       Date:  2005-03-18       Impact factor: 3.641

8.  Concentration of antipneumococcal antibodies as a serological correlate of protection: an application to acute otitis media.

Authors:  Jukka T Jokinen; Heidi Ahman; Terhi M Kilpi; P Helena Mäkelä; M Helena Käyhty
Journal:  J Infect Dis       Date:  2004-07-02       Impact factor: 5.226

9.  Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England.

Authors:  Nick Andrews; Ray Borrow; Elizabeth Miller
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

10.  Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  George R Siber; Ih Chang; Sherryl Baker; Philip Fernsten; Katherine L O'Brien; Mathuram Santosham; Keith P Klugman; Shabir A Madhi; Peter Paradiso; Robert Kohberger
Journal:  Vaccine       Date:  2007-02-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.